Peptides for tumour therapy and diagnosis: current status and future directions (1177 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Research Support, Non-U. S. Gov'T, Review,
Impact factor: 4.708, 5-year impact factor: 5.387
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-65649117755&partnerID=40&md5=cdd96a1100d9d9938e34dcf08a217bfa
Keywords: Cck, Integrin, Somatostatin, Structure-Activity Relationships, Tumour Diseases, 4 [[5 (8 Azaspiro[4 5]decan 8 Yl) 4 [(3, 5 Dichlorobenzoyl)amino] 5 Oxopentanoyl]amino] 5 (1 Naphthylamino) 5 Oxopentanoic Acid, Angiopeptin, Arginylglycylaspartic Acid, Cholecystokinin, Cholecystokinin Receptor, Cholecystokinin Receptor Blocking Agent, Cilengitide, Cr 2345, Cr 2767, Depreotide Tc 99m, Integrin Receptor, Itriglumide, Lorglumide, Loxiglumide, Nc 100692 Technetium Tc 99m, Octreotate[3 Tyrosine 1, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid Lu 177], Octreotide, Octreotide[3 Tyrosine 1, 10 Tetraacetic Acid Y 90], Pasireotide, Pentetreotide In 111, Proglumide, Radiopharmaceutical Agent, Somatostatin Derivative, Somatostatin Receptor, Spiroglumide, Unclassified Drug, Unindexed Drug, Vapreotide, Acromegaly, Antiangiogenic Activity, Breast Cancer, Cancer Chemotherapy, Cancer Diagnosis, Cancer Scintiscanning, Carcinoid, Clinical Trial, Diagnostic Accuracy, Drug Distribution, Drug Megadose, Drug Metabolism, Drug Receptor Binding, Drug Structure, Drug Synthesis, Gastrinoma, Gastrointestinal Tumor, Human, Isotope Labeling, Liver Metastasis, Neuroendocrine Tumor, Nonhuman, Paraganglioma, Protein Expression, Protein Targeting, Review, Single Photon Emission Computer Tomography, Thyroid Medullary Carcinoma, Amino Acid Sequence, Animals, Drug Delivery Systems, Molecular Sequence Data, Neoplasms, Peptides, 4 [[5 (8 Azaspiro [4 5] Decan 8 Yl) 4 [(3, 5 Dichlorobenzoyl) Amino] 5 Oxopentanoyl] Amino] 5 (1 Naphthylamino) 5 Oxopentanoic Acid, Octreotate [3 Tyrosine 1, Octreotide [3 Tyrosine 1,
Affiliations:
*** IBB - CNR ***
Department of Biological Sciences, University of Naples Federico II, via Mezzocannone 16, 80134, Napoli, Italy.
Institute of Biostructures and Bioimaging, CNR, University of Naples Federico II, via Mezzocannone 16, 80134 Napoli, Italy
References:
Okarvi, S.M., Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases (2004) Med. Res. Rev, 24, pp. 357-39
Biron, E., Chatterjee, J., Ovadia, O., Langenegger, D., Brueggen, J., Hoyer, D., Schmid, H.A., Kessler, H., Improving oral bioavailability of peptides by multiple N-methylation: Somatostatin analogues (2008) Angew. Chem. Int. Ed. Eng, 47, pp. 2595-2599
Patel, Y.C., Somatostatin and its receptor family (1999) Front. Neuroendocrinol, 20, pp. 157-198
Lewin, M.J., The somatostatin receptor in the GI tract (1992) Annu. Rev. Physiol, 54, pp. 455-468
Bousquet, C., Puente, E., Buscail, L., Vaysse, N., Susini, C., Antiproliferative effect of somatostatin and analogs (2001) Chemotherapy, 47 (SUPPL. 2), pp. 30-39
Hu, C., Yi, C., Hao, Z., Cao, S., Li, H., Shao, X., Zhang, J., Fan, D., (2004) Cancer Biol. Ther, 3, pp. 726-730
Bruno, J.F., Xu, Y., Song, J., Berelowitz, M., Molecular cloning and functional expression of a brain-specific somatostatin receptor (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 11151-11155
Meyerhof, W., The elucidation of somatostatin receptor functions: A current view (1998) Rev. Physiol. Biochem. Pharmacol, 133, pp. 55-108
Reisine, T., Bell, G.I., Molecular biology of somatostatin receptors (1995) Endocr. Rev, 16, pp. 427-442
Vanetti, M., Kouba, M., Wang, X., Vogt, G., Hollt, V., Cloning and expression of a novel mouse somatostatin receptor (SSTR2B) (1992) FEBS Lett, 311, pp. 290-294
Vanetti, M., Vogt, G., Hollt, V., The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization (1993) FEBS Lett, 331, pp. 260-266
Rocheville, M., Lange, D.C., Kumar, U., Sasi, R., Patel, R.C., Patel, Y.C., Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers (2000) J. Biol. Chem, 275, pp. 7862-7869
Pfeiffer, M., Koch, T., Schroder, H., Klutzny, M., Kirscht, S., Kreienkamp, H.J., Hollt, V., Schulz, S., Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A) (2001) J. Biol. Chem, 276, pp. 14027-14036
Rens-Domiano, S., Reisine, T., Biochemical and functional properties of somatostatin receptors (1987) J. Neurochem, 1992, p. 58
Schweitzer, P., Madamba, S., Siggins, G.R., Arachidonic acid metabolites as mediators of somatostatin-induced increase of neuronal M-current (1990) Nature, 346, pp. 464-467
Colas, B., Cambillau, C., Buscail, L., Zeggari, M., Esteve, J.P., Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells (1992) Eur. J. Biochem, 207, pp. 1017-1024
Pyronnet, S., Bousquet, C., Najib, S., Azar, R., Laklai, H., Antitumor effects of somatostatin (2008) Mol. Cell. Endocrinol, 286, pp. 230-237
Weckbecker, G., Lewis, I., Albert, R., Schmid, H.A., Hoyer, D., Opportunities in somatostatin research: Biological, chemical and therapeutic aspects (2003) Nat. Rev. Drug Discov, 2, pp. 999-1017
Oberg, K., Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment (2005) Curr. Opin. Oncol, 17, pp. 386-391
Solcia, E., Kloppel, G., Sobin, H., Histological typing of endocrine tumors (2000) World Health Organization International Histological Classification of Tumors
Volante, M., Rosas, R., Allia, E., Granata, R., Baragli, A., Muccioli, G., Papotti, M., Somatostatin, cortistatin and their receptors in tumours (2008) Mol. Cell Endocrinol, 286, pp. 219-229
Reubi, J.C., Peptide receptors as molecular targets for cancer diagnosis and therapy (2003) Endocrinol. Rev, 24, pp. 389-427
Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocrinol. Rev, 24, pp. 28-47
de Herder, W.W., Hofland, L.J., van der Lely, A.J., Lamberts, S.W., Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours (2003) Endocrinol. Relat. Cancer, 10, pp. 451-458
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action (1982) Life Sci, 31, pp. 1133-1140
Susini, C., Buscail, L., Rationale for the use of somatostatin analogs as antitumor agents (1733) Ann. Oncol, 2006, p. 17
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., Weckbecker, G., SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile (2002) Eur. J. Endocrinol, 146, pp. 707-716
Weckbecker, G., Briner, U., Lewis, I., Bruns, C., SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs (2002) Endocrinology, 143, pp. 4123-4130
van der Hoek, J., van der Lelij, A.J., Feelders, R.A., de Herder, W.W., Uitterlinden, P., Poon, K.W., Boerlin, V., Lamberts, S.W., The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients (2005) Clin. Endocrinol. (Oxf), 63, pp. 176-184
Schmid, H.A., Development, mechanism of action and potential applications (2008) Mol. Cell Endocrinol, 286, pp. 69-74
Schmid, H.A., Schoeffter, P., Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors (2004) Neuroendocrinology, 80 (SUPPL. 1), pp. 47-50
Valkema, R., De Jong, M., Bakker, W.H., Breeman, W.A., Kooij, P.P., Lugtenburg, P.J., De Jong, F.H., Krenning, E.P., Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience (2002) Semin. Nucl. Med, 32, pp. 110-122
McCarthy, K.E., Woltering, E.A., Anthony, L.B., In situ radiotherapy with 111In-pentetreotide (2000) Q. J. Nucl. Med, 44, pp. 88-95
Anthony, L.B., Woltering, E.A., Espenan, G.D., Cronin, M.D., Maloney, T.J., McCarthy, K.E., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies (2002) Semin. Nucl. Med, 32, pp. 123-132
Buscombe, J.R., Caplin, M.E., Hilson, A.J., Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors (2003) J. Nucl. Med, 44, pp. 1-6
Slooter, G.D., Breeman, W.A., Marquet, R.L., Krenning, E.P., van Eijck, C.H., Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver (1999) Int. J. Cancer, 81, pp. 767-771
Reubi, J.C., Schar, J.C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J.S., Macke, H.R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) Eur. J. Nucl. Med, 27, pp. 273-282
Reubi, J. C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1338-1347Ginj, M., Chen, J., Walter, M.A., Eltschinger, V., Reubi, J.C., Maecke, H.R., Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy (2005) Clin. Cancer Res, 11, pp. 1136-1145
Ginj, M., Schmitt, J.S., Chen, J., Waser, B., Reubi, J.C., de Jong, M., Schulz, S., Maecke, H.R., Design, synthesis, and biological evaluation of somatostatin-based radiopeptides (2006) Chem. Biol, 13, pp. 1081-1090
O'Donoghue, J.A., Bardies, M., Wheldon, T.E., Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides (1902) J. Nucl. Med, 1995, p. 36
de Jong, M., Breeman, W.A., Valkema, R., Bernard, B.F., Krenning, E.P., Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 13S-17S
Iten, F., Müller, B., Schindler, C., Rochlitz, C., Oertli, D., Mäcke, H.R., Müller-Brand, J., Walter, M.A., Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial (2007) Clin. Cancer Res, 13, pp. 6696-6702
Forrer, F., Valkema, R., Kwekkeboom, D.J., de Jong, M., Krenning, E.P., Neuroendocrine tumors. Peptide receptor radionuclide therapy (2007) Best Pract. Res. Clin. Endocrinol. Metab, 21, pp. 111-129
Forrer, F., Riedweg, I., Maecke, H.R., Mueller-Brand, J., Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma (2008) Q. J. Nucl. Med. Mol. Imaging, 52, pp. 334-340
Wehrmann, C., Senftleben, S., Zachert, C., Muller, D., Baum, R.P., Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC (2007) Cancer Biother. Radiopharm, 22, pp. 406-416
Davi, M.V., Bodei, L., Ferdeghini, M., Falconi, M., Testoni, M., Paganelli, G., Oliani, C., Francia, G., Multidisciplinary approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: A promising proposal (2008) Endocr. Pract, 14, pp. 213-218
Raju, M.R., Eisen, Y., Carpenter, S., Inkret, W.C., Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus (1991) Radiat. Res, 128, pp. 204-209
Geerlings, M. W., Sr.
Geerlings, M. W., Jr.
Scheinberg, D. A. Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med., 1999, 40, 166-176Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., Essler, M., Preclinical Evaluation of the {alpha}-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors (2008) Clin. Cancer Res, 14, pp. 3555-3561
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Reubi, J.C., Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 16436-16441
Janson, E.T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother. Biol. Response Modif, 21, pp. 535-546
Gabriel, M., Decristoforo, C., Donnemiller, E., Ulmer, H., Watfah Rychlinski, C., Mather, S.J., Moncayo, R., An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPAoctreotide for diagnosis of somatostatin receptor-expressing tumors (2003) J. Nucl. Med, 44, pp. 708-716
Czepczynski, R., Parisella, M.G., Kosowicz, J., Mikolajczak, R., Ziemnicka, K., Gryczynska, M., Sowinski, J., Signore, A., Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma (2007) Eur. J. Nucl. Med. Mol. Imaging, 34, pp. 1635-1645
Cwikla, J.B., Mikolajczak, R., Pawlak, D., Buscombe, J.R., Nasierowska-Guttmejer, A., Bator, A., Maecke, H.R., Walecki, J., Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs (2008) J. Nucl. Med, 49, pp. 1060-1065
Vallabhajosula, S., Moyer, B.R., Lister-James, J., McBride, B.J., Lipszyc, H., Lee, H., Bastidas, D., Dean, R.T., Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides (1996) J. Nucl. Med, 37, pp. 1016-1022
Menda, Y., Kahn, D., Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide (2002) Semin. Nucl. Med, 32, pp. 92-96
Blum, J., Handmaker, H., Lister-James, J., Rinne, N., A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules (2000) Chest, 117, pp. 1232-1238
Shah, T., Kulakiene, I., Quigley, A.M., Warbey, V.S., Srirajaskanthan, R., Toumpanakis, C., Hochhauser, D., Caplin, M.E., The role of 99mTc-depreotide in the management of neuroendocrine tumours (2008) Nucl. Med. Commun, 29, pp. 436-440
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R.P., Reubi, J.C., Maecke, H., Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? (2007) Eur. J. Nucl. Med. Mol. Imaging, 34, pp. 982-993
Baum, R., Schmucking, M., Wortmann, R., Muller, M., Zhernosekov, K., Rosch, F., Receptor PET/CT using the Ga-68 labelled somatostatin analog DOTA-1-Nal3-octreotide (DOTA-NOC): Clinical experience in 140 patients (2005) Nuklearmedizin, 44, pp. A57
Hofmann, M., Oei, M., Boerner, A.R., Maecke, H., Geworski, L., Knapp, W.H., Krause, T., Comparison of Ga-68-DOTATOC and Ga-68-DOTANOC for radiopeptide PET (2005) Nuklearmedizin, 44, pp. A58
Win, Z., Rahman, L., Murrell, J., Todd, J., Al-Nahhas, A., The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 506
Traub, T., von Guggenberg, E., Kendler, D., Eisterer, W., Bale, R., Dobrozemsky, G., Gabriel, M., Virgolini, I., First experience with Ga-68-DOTA-lanreotide PET in tumor patients (2005) Nuklearmedizin, 44, pp. A198
Hofmann, M., Maecke, H., Borner, R., Weckesser, E., Schoffski, P., Oei, L., Schumacher, J., Knapp, H., Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data (1751) Eur. J. Nucl. Med, 2001, p. 28
Win, Z., Al-Nahhas, A., Rubello, D., Gross, M.D., Somatostatin receptor PET imaging with Gallium-68 labeled peptides (2007) Q. J. Nucl. Med. Mol. Imaging, 51, pp. 244-250
Meisetschlager, G., Poethko, T., Stahl, A., Wolf, I., Scheidhauer, K., Schottelius, M., Herz, M., Schwaiger, M., (2006) J. Nucl. Med, 47, pp. 566-573
Schottelius, M., Poethko, T., Herz, M., Reubi, J.C., Kessler, H., Schwaiger, M., Wester, H.J., First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography (2004) Clin. Cancer Res, 10, pp. 3593-3606
Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease (1995) Nat. Med, 1, pp. 27-31
Mousa, S.A., Mechamism of angiogensis in vascular disorders: Potential therapeutic targets (1998) Drugs Future, 23, pp. 51-60
Mousa, S.A., Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications (2000) Emerging Ther. Targets, 4, pp. 389-395
Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis (2000) Nat. Med, 6, pp. 389-395
Bogler, O., Mikkelsen, T., Angiogenesis in glioma: Molecular mechanisms and roadblocks to translation (2003) Cancer J, 9, pp. 205-213
Folkman, J., Role of angiogenesis in tumor growth and metastasis (2002) Semin. Oncol, 29, pp. 15-18
Hwang, R., Varner, J., The role of integrins in tumor angiogenesis (2004) Hematol. Oncol. Clin. North Am, 18, pp. 991-1006. , vii
Ellis, L.M., Liu, W., Fan, F., Jung, Y.D., Reinmuth, N., Stoeltzing, O., Takeda, A., Ahmad, S., Synopsis of angiogenesis inhibitors in oncology (2002) Oncology (Williston Park), 16, pp. 14-22
Jin, H., Varner, J., Integrins: Roles in cancer development and as treatment targets (2004) Br. J. Cancer, 90, pp. 561-565
Kumar, C.C., Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis (2003) Curr. Drug Targets, 4, pp. 123-131
Brooks, P.C., Clark, R.A., Cheresh, D.A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Ruoslahti, E., Pierschbacher, M.D., New perspectives in cell adhesion: RGD and integrins (1987) Science, 238, pp. 491-497
Ivaska, J., Heino, J., Adhesion receptors and cell invasion: Mechanisms of integrin-guided degradation of extracellular matrix (2000) Cell Mol. Life Sci, 57, pp. 16-24
Hynes, R.O., Integrins: Versatility, modulation, and signaling in cell adhesion (1992) Cell, 69, pp. 11-25
Felding-Habermann, B., O'Toole, T.E., Smith, J.W., Fransvea, E., Ruggeri, Z.M., Ginsberg, M.H., Hughes, P.E., Mueller, B.M., Integrin activation controls metastasis in human breast cancer (1853) Proc. Natl. Acad. Sci. USA, 2001, p. 98
Reinmuth, N., Liu, W., Ahmad, S.A., Fan, F., Stoeltzing, O., Parikh, A.A., Bucana, C.D., Ellis, L.M., Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice (2003) Cancer Res, 63, pp. 2079-2087
Zhao, Y., Bachelier, R., Treilleux, I., Pujuguet, P., Peyruchaud, O., Baron, R., Clement-Lacroix, P., Clezardin, P., Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases (2007) Cancer Res, 67, pp. 5821-5830
Eliceiri, B.P., Cheresh, D.A., The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development (1999) J. Clin. Invest, 103, pp. 1227-1230
Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 1996, 12, 697-715Horton, M.A., The alpha v beta 3 integrin "vitronectin receptor (1997) Int. J Biochem. Cell Biol, 29, pp. 721-725
Bello, L., Francolini, M., Marthyn, P., Zhang, J., Carroll, R.S., Nikas, D.C., Strasser, J.F., Black, P.M., Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery (2001) Neurosurgery, 49, pp. 380-389
Gurrath, M., Muller, G., Kessler, H., Aumailley, M., Timpl, R., Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides (1992) Eur. J. Biochem, 210, pp. 911-921
Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins (1994) J. Biol. Chem, 269, pp. 20233-20238
Plow, E.F., Haas, T.A., Zhang, L., Loftus, J., Smith, J.W., Ligand binding to integrins (2000) J. Biol. Chem, 275, pp. 21785-21788
Suehiro, K., Smith, J.W., Plow, E.F., The ligand recognition specificity of beta3 integrins (1996) J. Biol. Chem, 271, pp. 10365-10371
Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C.A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Falcioni, R., Cimino, L., Gentileschi, M.P., D'Agnano, I., Zupi, G., Kennel, S.J., Sacchi, A., Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes (1994) Exp. Cell Res, 210, pp. 113-122
Meitar, D., Crawford, S.E., Rademaker, A.W., Cohn, S.L., Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma (1996) J. Clin. Oncol, 14, pp. 405-414
Gasparini, G., Brooks, P.C., Biganzoli, E., Vermeulen, P.B., Bonoldi, E., Dirix, L.Y., Ranieri, G., Cheresh, D.A., Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer (1998) Clin. Cancer Res, 4, pp. 2625-2634
Sengupta, S., Chattopadhyay, N., Mitra, A., Ray, S., Dasgupta, S., Chatterjee, A., Role of alphavbeta3 integrin receptors in breast tumor (2001) J. Exp. Clin. Cancer Res, 20, pp. 585-590
Zitzmann, S., Ehemann, V., Schwab, M., Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo (2002) Cancer Res, 62, pp. 5139-5143
Weber, W.A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H.J., Schwaiger, M., Tumor angiogenesis targeting using imaging agents (2001) Q. J. Nucl. Med, 45, pp. 179-182
Costouros, N.G., Diehn, F.E., Libutti, S.K., Molecular imaging of tumor angiogenesis (2002) J. Cell Biochem. Suppl, 39, pp. 72-78
Van De Wiele, C., Oltenfreiter, R., De Winter, O., Signore, A., Slegers, G., Dierckx, R.A., Tumour angiogenesis pathways: Related clinical issues and implications for nuclear medicine imaging (2002) Eur. J. Nucl. Med. Mol. Imaging, 29, pp. 699-709
Liu, S., Robinson, S.P., Edwards, D.S., Integrin alphaV beta3 directed radiopharmaceutical for tumor imaging (2003) Drugs Future, 28, pp. 551-564
Haubner, R., Wester, H.J., Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies (2004) Curr. Pharm. Des, 10, pp. 1439-1455
Chen, X., Multimodality imaging of tumor integrin alphavbeta3 expression (2006) Mini Rev. Med. Chem, 6, pp. 227-234
Haubner, R., Finsinger, D., Kessler, H., Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alphaVbeta3 integrin for a new cancer therapy (1997) Angew. Chem. Int. Ed. Engl, 36, pp. 1374-1389
Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., Cheresh, D.A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) Cell, 79, pp. 1157-1164
Clezardin, P., Recent insights into the role of integrins in cancer metastasis (1998) Cell Mol. Life Sci, 54, pp. 541-548
Aumailley, M., Gurrath, M., Muller, G., Calvete, J., Timpl, R., Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 (1991) FEBS Lett, 291, pp. 50-54
Haubner, R., Gratias, R., Diefenbach, B., Goodman, S.L., Jonczyk, A., Kessler, H.P., Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin alphaVbeta3 Antagonists (1996) J. Am. Chem. Soc, 118, pp. 7461-7472
Gottschalk, K.E., Kessler, H., The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction (2002) Angew. Chem. Int. Ed. Engl, 41, pp. 3767-3774
Bach II, A.C., Espina, J.R., Jackson, S.A., Stouten, P.F.W., Duke, J.L., Mousa, S.A., DeGrado, W.F., Type II' to Type I -Turn Swap Changes Specificity for Integrins (1996) J. Am. Chem. Soc, 118, pp. 293-294
Muller, G., Gurrath, M., Kessler, H., Pharmacophore refinement of gpIIb/ IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides (1994) J. Comput. Aided Mol. Des, 8, pp. 709-730
Scarborough, R.M., Naughton, M.A., Teng, W., Rose, J.W., Phillips, D.R., Nannizzi, L., Arfsten, A., Charo, I.F., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa (1993) J. Biol. Chem, 268, pp. 1066-1073
Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists (1999) J. Med. Chem, 42, pp. 3033-3040
Eskens, F.A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur. J. Cancer, 39, pp. 917-926
Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD (2005) PLoS Med, 2, pp. e70
Tempia-Caliera, A. A.
Nippgen, J. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285Beekman, K.W., Colevas, A.D., Cooney, K., Dipaola, R., Dunn, R.L., Gross, M., Keller, E.T., Hussain, M., Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design (2006) Clin. Genitourin Cancer, 4, pp. 299-302
Nabors, L.B., Mikkelsen, T., Rosenfeld, S.S., Hochberg, F., Akella, N.S., Fisher, J.D., Cloud, G.A., Grossman, S.A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma (2007) J. Clin. Oncol, 25, pp. 1651-1657
Garanger, E., Boturyn, D., Dumy, P., Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents (2007) Med. Chem, 7, pp. 552-558
MacDonald, T.J., Stewart, C.F., Kocak, M., Goldman, S., Ellenbogen, R.G., Phillips, P., Lafond, D., Kun, L.E., Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012 (2008) J. Clin. Oncol, 26, pp. 919-924
Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Arnaout, M.A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Thumshirn, G., Hersel, U., Goodman, S.L., Kessler, H., Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation (2003) Chemistry, 9, pp. 2717-2725
Wester, H.J., Kessler, H., Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? (1940) J. Nucl. Med, 2005, p. 46
Boturyn, D., Coll, J.L., Garanger, E., Favrot, M.C., Dumy, P., Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis (2004) J. Am. Chem. Soc, 126, pp. 5730-5739
Liu, S., Hsieh, W.Y., Kim, Y.S., Mohammed, S.I., Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer (2005) Bioconjug. Chem, 16, pp. 1580-1588
de Visser, M., Verwijnen, S.M., de Jong, M., Update: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy (2008) Cancer Biother. Radiopharm, 23, pp. 137-157
Meyer, A., Auernheimer, J., Modlinger, A., Kessler, H., Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting (2006) Curr. Pharm. Des, 12, pp. 2723-2747
Psimadas, D., Fani, M., Zikos, C., Xanthopoulos, S., Archimandritis, S.C., Varvarigou, A.D., Study of the labeling of two novel RGD-peptidic derivatives with the precursor [99mTc(H2O)3 (CO)3]+ and evaluation for early angiogenesis detection in cancer (2006) Appl. Radiat. Isot, 64, pp. 151-159
Lee, Y.S., Jeong, J.M., Kim, H.W., Chang, Y.S., Kim, Y.J., Hong, M.K., Rai, G.B., Suh, Y.G., An improved method of 18F peptide labeling: Hydrazone formation with HYNIC-conjugated c(RGDyK) (2006) Nucl. Med. Biol, 33, pp. 677-683
Decristoforo, C., Faintuch-Linkowski, B., Rey, A., von Guggenberg, E., Rupprich, M., Hernandez-Gonzales, I., Rodrigo, T., Haubner, R., 99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression (2006) Nucl. Med. Biol, 33, pp. 945-952
Jia, B., Shi, J., Yang, Z., Xu, B., Liu, Z., Zhao, H., Liu, S., Wang, F., 99mTc-labeled cyclic RGDfK dimer: Initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression (2006) Bioconjug. Chem, 17, pp. 1069-1076
Liu, S., Edwards, D.S., Ziegler, M.C., Harris, A.R., Hemingway, S.J., Barrett, J.A., 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors (2001) Bioconjug. Chem, 12, pp. 624-629
Mitra, A., Coleman, T., Borgman, M., Nan, A., Ghandehari, H., Line, B.R., Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting (2006) J. Control Rel, 114, pp. 175-183
Dijkgraaf, I., Kruijtzer, J.A., Frielink, C., Soede, A.C., Hilbers, H.W., Oyen, W.J., Corstens, F.H., Boerman, O.C., Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists (2006) Nucl. Med. Biol, 33, pp. 953-961
Dijkgraaf, I., Rijnders, A.Y., Soede, A., Dechesne, A.C., van Esse, G.W., Brouwer, A.J., Corstens, F.H., Liskamp, R.M., Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: Implications for tumor targeting and tumor imaging purposes (2007) Org. Biomol. Chem, 5, pp. 935-944
Dijkgraaf, I., Liu, S., Kruijtzer, J.A., Soede, A.C., Oyen, W.J., Liskamp, R.M., Corstens, F.H., Boerman, O.C., Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide (2007) Nucl. Med. Biol, 34, pp. 29-35
Zhang, X., Chen, X., Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent (2007) Appl. Radiat. Isot, 65, pp. 70-78
Alves, S., Correia, J.D., Gano, L., Rold, T.L., Prasanphanich, A., Haubner, R., Rupprich, M., Smith, C.J., In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys) (2007) Bioconjug. Chem, 18, pp. 530-537
Chen, X. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J. Nucl. Med., 2007, 48, 1536-1544Li, Z.B., Wu, Z., Chen, K., Chin, F.T., Chen, X., Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression (1987) Bioconjug. Chem, 2007, p. 18
Li, Z.B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., Chen, X., (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression (2007) J. Nucl. Med, 48, pp. 1162-1171
Li, Z.B., Chen, K., Chen, X., (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression (2008) Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 1100-1108
Edwards, D., Jones, P., Haramis, H., Battle, M., Lear, R., Barnett, D.J., Edwards, C., Godden, V., 99mTc-NC100692 - a tracer for imaging vitronectin receptors associated with angiogenesis: A preclinical investigation (2008) Nucl. Med. Biol, 35, pp. 365-375
Roed, L., Oulie, I., Knuttel, T., Toft, K.G., Hustvedt, S.O., Skotland, T., Metabolism in rats of NC100692, an RGD-peptide for imaging of angiogenesis (2008) J. Pharm. Biomed. Anal, 47, pp. 164-169
Indrevoll, B., Kindberg, G.M., Solbakken, M., Bjurgert, E., Johansen, J.H., Karlsen, H., Mendizabal, M., Cuthbertson, A., NC-100717: A versatile RGD peptide scaffold for angiogenesis imaging (2006) Bioorg. Med.Chem. Lett, 16, pp. 6190-6193
Hua, J., Dobrucki, L.W., Sadeghi, M.M., Zhang, J., Bourke, B.N., Cavaliere, P., Song, J., Sinusas, A.J., Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia (2005) Circulation, 111, pp. 3255-3260
Lindsey, M.L., Escobar, G.P., Dobrucki, L.W., Goshorn, D.K., Bouges, S., Mingoia, J.T., McClister Jr., D.M., Spinale, F.G., Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction (2006) Am. J. Physiol. Heart Circ. Physiol, 290, pp. H232-H239
Bach-Gansmo, T., Danielsson, R., Saracco, A., Wilczek, B., Bogsrud, T.V., Fangberget, A., Tangerud, A., Tobin, D., Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692 (2006) J. Nucl. Med, 47, pp. 1434-1439
Glaser, M., Morrison, M., Solbakken, M., Arukwe, J., Karlsen, H., Wiggen, U., Champion, S., Cuthbertson, A., Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups (2008) Bioconjug. Chem, 19, pp. 951-957
Del Gatto, A., Zaccaro, L., Grieco, P., Novellino, E., Zannetti, A., Novel and selective alpha(v)beta3 receptor peptide antagonist: Design, synthesis, and biological behavior (2006) J. Med. Chem, 49, pp. 3416-3420
de Tullio, P., Delarge, J., Pirotte, B., Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists) (1999) Curr. Med. Chem, 6, pp. 433-455
Escherich, A., Lutz, J., Escrieut, C., Fourmy, D., van Neuren, A.S., Muller, G., Schafferhans, A., Moroder, L., Peptide/ benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors (2000) Biopolymers, 56, pp. 55-76
Herranz, R., Cholecystokinin antagonists: Pharmacological and therapeutic potential (2003) Med. Res. Rev, 23, pp. 559-605
Reubi, J.C., Schaer, J.C., Waser, B., Cholecystokinin(CCK)-A and CCK-B/ gastrin receptors in human tumors (1997) Cancer Res, 57, pp. 1377-1386
Berna, M.J., Jensen, R.T., Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases (2007) Curr. Top. Med. Chem, 7, pp. 1211-1231
Baldwin, G.S., Shulkes, A., CCK receptors and cancer (2007) Curr. Top. Med. Chem, 7, pp. 1232-1238
Reubi, J.C., Targeting CCK receptors in human cancers (2007) Curr. Top. Med. Chem, 7, pp. 1239-1242
Reubi, J.C., Macke, H.R., Krenning, E.P., Candidates for peptide receptor radiotherapy today and in the future (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 67S-75S
Laverman, P., Behe, M., Oyen, W.J., Willems, P.H., Corstens, F.H., Behr, T.M., Boerman, O.C., Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors (2004) Bioconjug. Chem, 15, pp. 561-568
Wank, S.A., Cholecystokinin receptors (1995) Am. J. Physiol, 269, pp. G628-G646
Mansi, R., Tesauro, D., De Capua, A., Fattorusso, R., Caraco, C., Aloj, L., Benedetti, E., Morelli, G., Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (2004) Biopolymers, 76, pp. 527-534
Aloj, L., Panico, M., Caraco, C., Del Vecchio, S., Arra, C., Affuso, A., Accardo, A., Salvatore, M., In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (2004) Cancer Biother. Radiopharm, 19, pp. 93-98
Aloj, L., Caraco, C., Panico, M., Zannetti, A., Del Vecchio, S., Tesauro, D., De Luca, S., Salvatore, M., In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (2004) J. Nucl. Med, 45, pp. 485-494
D'Andrea, L.D., Testa, I., Panico, M., Di Stasi, R., Caraco, C., Tarallo, L., Arra, C., Aloj, L., In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with (99m)Tc-tricarbonyl (2008) Biopolymers, 90, pp. 707-712
Berna, M.J., Tapia, J.A., Sancho, V., Jensen, R.T., Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential (2007) Curr. Opin. Pharmacol, 7, pp. 583-592
De Luca, S., De Capua, A., Saviano, M., Della Moglie, R., Aloj, L., Tarallo, L., Pedone, C., Morelli, G., Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor (2007) Bioorg. Med. Chem, 15, pp. 5845-5853
De Luca, S., Saviano, M., Della Moglie, R., Digilio, G., Bracco, C., Aloj, L., Tarallo, L., Morelli, G., (2006) Chem. Med. Chem, 1, pp. 997-1006
De Luca, S., Morelli, G., Synthesis and characterization of a sulfated and a non-sulfated cyclic CCK8 analogue functionalized with a chelating group for metal labelling (2004) J. Pept. Sci, 10, pp. 265-273
De Luca, S., Ragone, R., Bracco, C., Digilio, G., Aloj, L., Tesauro, D., Saviano, M., Morelli, G., A cyclic CCK8 analogue selective for the cholecystokinin type A receptor: Design, synthesis, NMR structure and binding measurements (2003) Chembiochem, 4, pp. 1176-1187
Morelli, G., De Luca, S., Tesauro, D., Saviano, M., Pedone, C., Dolmella, A., Visentin, R., Mazzi, U., CCK8 peptide derivatized with diphenylphosphine for rhenium labelling: Synthesis and molecular mechanics calculations (2002) J. Pept. Sci, 8, pp. 373-381
Rovati, A.L., Casula, P.L., Da Re, G., Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid)] (1967) Minerva Med, 58, pp. 3656-3670
Rovati, A.L., Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents (1976) Scand. J. Gastroenterol. Suppl, 42, pp. 113-118
Makovec, F., Bani, M., Cereda, R., Chiste, R., Pacini, M.A., Revel, L., Rovati, L.A., Setnikar, I., Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists (1987) Arzneimittelforschung, 37, pp. 1265-1268
Setnikar, I., Bani, M., Cereda, R., Chiste, R., Makovec, F., Pacini, M.A., Revel, L., Anticholecystokinin activities of loxiglumide (1987) Arzneimittelforschung, 37, pp. 1168-1171
Makovec, F., Peris, W., Revel, L., Giovanetti, R., Mennuni, L., Rovati, L.C., Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives (1992) J. Med. Chem, 35, pp. 28-38
Revel, L., Ferrari, F., Makovec, F., Rovati, L.C., Impicciatore, M., Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative (1992) Eur. J. Pharmacol, 216, pp. 217-224
Salerni, B. nhibitory effect of a gastrin receptor antagonist, CR2945, on 1, 2-dimethylhydrazine-induced colorectal cancer in mice. Eur. Surg. Res., 1999, 31, 406-411Giragossian, C., Mierke, D.F., Determination of ligand-receptor interactions of cholecystokinin by nuclear magnetic resonance (2003) Life Sci, 73, pp. 705-713
Okarvi, S. M., Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases (2004) Med. Res. Rev, 24, pp. 357-39
Patel, Y. C., Somatostatin and its receptor family (1999) Front. Neuroendocrinol, 20, pp. 157-198
Lewin, M. J., The somatostatin receptor in the GI tract (1992) Annu. Rev. Physiol, 54, pp. 455-468
Bruno, J. F., Xu, Y., Song, J., Berelowitz, M., Molecular cloning and functional expression of a brain-specific somatostatin receptor (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 11151-11155
Reubi, J. C., Peptide receptors as molecular targets for cancer diagnosis and therapy (2003) Endocrinol. Rev, 24, pp. 389-427
Hofland, L. J., Lamberts, S. W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocrinol. Rev, 24, pp. 28-47
de Herder, W. W., Hofland, L. J., van der Lely, A. J., Lamberts, S. W., Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours (2003) Endocrinol. Relat. Cancer, 10, pp. 451-458
Schmid, H. A., Development, mechanism of action and potential applications (2008) Mol. Cell Endocrinol, 286, pp. 69-74
Schmid, H. A., Schoeffter, P., Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors (2004) Neuroendocrinology, 80 (SUPPL. 1), pp. 47-50
McCarthy, K. E., Woltering, E. A., Anthony, L. B., In situ radiotherapy with 111In-pentetreotide (2000) Q. J. Nucl. Med, 44, pp. 88-95
Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., McCarthy, K. E., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies (2002) Semin. Nucl. Med, 32, pp. 123-132
Buscombe, J. R., Caplin, M. E., Hilson, A. J., Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors (2003) J. Nucl. Med, 44, pp. 1-6
Slooter, G. D., Breeman, W. A., Marquet, R. L., Krenning, E. P., van Eijck, C. H., Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver (1999) Int. J. Cancer, 81, pp. 767-771
Reubi, J. C., Schar, J. C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., Macke, H. R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) Eur. J. Nucl. Med, 27, pp. 273-282
O'Donoghue, J. A., Bardies, M., Wheldon, T. E., Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides (1902) J. Nucl. Med, 1995, p. 36
Iten, F., M ller, B., Schindler, C., Rochlitz, C., Oertli, D., M cke, H. R., M ller-Brand, J., Walter, M. A., Response to [90Yttrium-DOTA] -TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial (2007) Clin. Cancer Res, 13, pp. 6696-6702
Davi, M. V., Bodei, L., Ferdeghini, M., Falconi, M., Testoni, M., Paganelli, G., Oliani, C., Francia, G., Multidisciplinary approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3] -octreotide) and 177Lu DOTATATE ([177Lu-DOTA0, Tyr3] -octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: A promising proposal (2008) Endocr. Pract, 14, pp. 213-218
Raju, M. R., Eisen, Y., Carpenter, S., Inkret, W. C., Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus (1991) Radiat. Res, 128, pp. 204-209
Janson, E. T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother. Biol. Response Modif, 21, pp. 535-546
Cwikla, J. B., Mikolajczak, R., Pawlak, D., Buscombe, J. R., Nasierowska-Guttmejer, A., Bator, A., Maecke, H. R., Walecki, J., Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs (2008) J. Nucl. Med, 49, pp. 1060-1065
Mousa, S. A., Mechamism of angiogensis in vascular disorders: Potential therapeutic targets (1998) Drugs Future, 23, pp. 51-60
Mousa, S. A., Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications (2000) Emerging Ther. Targets, 4, pp. 389-395
Ellis, L. M., Liu, W., Fan, F., Jung, Y. D., Reinmuth, N., Stoeltzing, O., Takeda, A., Ahmad, S., Synopsis of angiogenesis inhibitors in oncology (2002) Oncology (Williston Park), 16, pp. 14-22
Kumar, C. C., Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis (2003) Curr. Drug Targets, 4, pp. 123-131
Brooks, P. C., Clark, R. A., Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Hynes, R. O., Integrins: Versatility, modulation, and signaling in cell adhesion (1992) Cell, 69, pp. 11-25
Eliceiri, B. P., Cheresh, D. A., The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development (1999) J. Clin. Invest, 103, pp. 1227-1230
Plow, E. F., Haas, T. A., Zhang, L., Loftus, J., Smith, J. W., Ligand binding to integrins (2000) J. Biol. Chem, 275, pp. 21785-21788
Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C. A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H. J., Schwaiger, M., Tumor angiogenesis targeting using imaging agents (2001) Q. J. Nucl. Med, 45, pp. 179-182
Costouros, N. G., Diehn, F. E., Libutti, S. K., Molecular imaging of tumor angiogenesis (2002) J. Cell Biochem. Suppl, 39, pp. 72-78
Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., Cheresh, D. A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) Cell, 79, pp. 1157-1164
Gottschalk, K. E., Kessler, H., The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction (2002) Angew. Chem. Int. Ed. Engl, 41, pp. 3767-3774
Bach II, A. C., Espina, J. R., Jackson, S. A., Stouten, P. F. W., Duke, J. L., Mousa, S. A., DeGrado, W. F., Type II' to Type I -Turn Swap Changes Specificity for Integrins (1996) J. Am. Chem. Soc, 118, pp. 293-294
Scarborough, R. M., Naughton, M. A., Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L., Arfsten, A., Charo, I. F., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa (1993) J. Biol. Chem, 268, pp. 1066-1073
Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists (1999) J. Med. Chem, 42, pp. 3033-3040
Eskens, F. A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur. J. Cancer, 39, pp. 917-926
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Grossman, S. A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma (2007) J. Clin. Oncol, 25, pp. 1651-1657
MacDonald, T. J., Stewart, C. F., Kocak, M., Goldman, S., Ellenbogen, R. G., Phillips, P., Lafond, D., Kun, L. E., Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012 (2008) J. Clin. Oncol, 26, pp. 919-924
Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Arnaout, M. A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Wester, H. J., Kessler, H., Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? (1940) J. Nucl. Med, 2005, p. 46
Liu, S., Hsieh, W. Y., Kim, Y. S., Mohammed, S. I., Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer (2005) Bioconjug. Chem, 16, pp. 1580-1588
Lee, Y. S., Jeong, J. M., Kim, H. W., Chang, Y. S., Kim, Y. J., Hong, M. K., Rai, G. B., Suh, Y. G., An improved method of 18F peptide labeling: Hydrazone formation with HYNIC-conjugated c (RGDyK) (2006) Nucl. Med. Biol, 33, pp. 677-683
Li, Z. B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., Chen, X., (64) Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha (v) beta (3) integrin expression (2007) J. Nucl. Med, 48, pp. 1162-1171
Li, Z. B., Chen, K., Chen, X., (68) Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha (v) beta (3) expression (2008) Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 1100-1108
Lindsey, M. L., Escobar, G. P., Dobrucki, L. W., Goshorn, D. K., Bouges, S., Mingoia, J. T., McClister Jr., D. M., Spinale, F. G., Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction (2006) Am. J. Physiol. Heart Circ. Physiol, 290, pp. H232-H239
Reubi, J. C., Schaer, J. C., Waser, B., Cholecystokinin (CCK) -A and CCK-B/ gastrin receptors in human tumors (1997) Cancer Res, 57, pp. 1377-1386
Berna, M. J., Jensen, R. T., Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases (2007) Curr. Top. Med. Chem, 7, pp. 1211-1231
Baldwin, G. S., Shulkes, A., CCK receptors and cancer (2007) Curr. Top. Med. Chem, 7, pp. 1232-1238
Reubi, J. C., Targeting CCK receptors in human cancers (2007) Curr. Top. Med. Chem, 7, pp. 1239-1242
Reubi, J. C., Macke, H. R., Krenning, E. P., Candidates for peptide receptor radiotherapy today and in the future (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 67S-75S
Wank, S. A., Cholecystokinin receptors (1995) Am. J. Physiol, 269, pp. G628-G646
D'Andrea, L. D., Testa, I., Panico, M., Di Stasi, R., Caraco, C., Tarallo, L., Arra, C., Aloj, L., In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with (99m) Tc-tricarbonyl (2008) Biopolymers, 90, pp. 707-712
Berna, M. J., Tapia, J. A., Sancho, V., Jensen, R. T., Progress in developing cholecystokinin (CCK) /gastrin receptor ligands that have therapeutic potential (2007) Curr. Opin. Pharmacol, 7, pp. 583-592
Rovati, A. L., Casula, P. L., Da Re, G., Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid)] (1967) Minerva Med, 58, pp. 3656-3670
Rovati, A. L., Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents (1976) Scand. J. Gastroenterol. Suppl, 42, pp. 113-118
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Research Support, Non-U. S. Gov'T, Review,
Impact factor: 4.708, 5-year impact factor: 5.387
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-65649117755&partnerID=40&md5=cdd96a1100d9d9938e34dcf08a217bfa
Keywords: Cck, Integrin, Somatostatin, Structure-Activity Relationships, Tumour Diseases, 4 [[5 (8 Azaspiro[4 5]decan 8 Yl) 4 [(3, 5 Dichlorobenzoyl)amino] 5 Oxopentanoyl]amino] 5 (1 Naphthylamino) 5 Oxopentanoic Acid, Angiopeptin, Arginylglycylaspartic Acid, Cholecystokinin, Cholecystokinin Receptor, Cholecystokinin Receptor Blocking Agent, Cilengitide, Cr 2345, Cr 2767, Depreotide Tc 99m, Integrin Receptor, Itriglumide, Lorglumide, Loxiglumide, Nc 100692 Technetium Tc 99m, Octreotate[3 Tyrosine 1, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid Lu 177], Octreotide, Octreotide[3 Tyrosine 1, 10 Tetraacetic Acid Y 90], Pasireotide, Pentetreotide In 111, Proglumide, Radiopharmaceutical Agent, Somatostatin Derivative, Somatostatin Receptor, Spiroglumide, Unclassified Drug, Unindexed Drug, Vapreotide, Acromegaly, Antiangiogenic Activity, Breast Cancer, Cancer Chemotherapy, Cancer Diagnosis, Cancer Scintiscanning, Carcinoid, Clinical Trial, Diagnostic Accuracy, Drug Distribution, Drug Megadose, Drug Metabolism, Drug Receptor Binding, Drug Structure, Drug Synthesis, Gastrinoma, Gastrointestinal Tumor, Human, Isotope Labeling, Liver Metastasis, Neuroendocrine Tumor, Nonhuman, Paraganglioma, Protein Expression, Protein Targeting, Review, Single Photon Emission Computer Tomography, Thyroid Medullary Carcinoma, Amino Acid Sequence, Animals, Drug Delivery Systems, Molecular Sequence Data, Neoplasms, Peptides, 4 [[5 (8 Azaspiro [4 5] Decan 8 Yl) 4 [(3, 5 Dichlorobenzoyl) Amino] 5 Oxopentanoyl] Amino] 5 (1 Naphthylamino) 5 Oxopentanoic Acid, Octreotate [3 Tyrosine 1, Octreotide [3 Tyrosine 1,
Affiliations:
*** IBB - CNR ***
Department of Biological Sciences, University of Naples Federico II, via Mezzocannone 16, 80134, Napoli, Italy.
Institute of Biostructures and Bioimaging, CNR, University of Naples Federico II, via Mezzocannone 16, 80134 Napoli, Italy
References:
Okarvi, S.M., Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases (2004) Med. Res. Rev, 24, pp. 357-39
Biron, E., Chatterjee, J., Ovadia, O., Langenegger, D., Brueggen, J., Hoyer, D., Schmid, H.A., Kessler, H., Improving oral bioavailability of peptides by multiple N-methylation: Somatostatin analogues (2008) Angew. Chem. Int. Ed. Eng, 47, pp. 2595-2599
Patel, Y.C., Somatostatin and its receptor family (1999) Front. Neuroendocrinol, 20, pp. 157-198
Lewin, M.J., The somatostatin receptor in the GI tract (1992) Annu. Rev. Physiol, 54, pp. 455-468
Bousquet, C., Puente, E., Buscail, L., Vaysse, N., Susini, C., Antiproliferative effect of somatostatin and analogs (2001) Chemotherapy, 47 (SUPPL. 2), pp. 30-39
Hu, C., Yi, C., Hao, Z., Cao, S., Li, H., Shao, X., Zhang, J., Fan, D., (2004) Cancer Biol. Ther, 3, pp. 726-730
Bruno, J.F., Xu, Y., Song, J., Berelowitz, M., Molecular cloning and functional expression of a brain-specific somatostatin receptor (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 11151-11155
Meyerhof, W., The elucidation of somatostatin receptor functions: A current view (1998) Rev. Physiol. Biochem. Pharmacol, 133, pp. 55-108
Reisine, T., Bell, G.I., Molecular biology of somatostatin receptors (1995) Endocr. Rev, 16, pp. 427-442
Vanetti, M., Kouba, M., Wang, X., Vogt, G., Hollt, V., Cloning and expression of a novel mouse somatostatin receptor (SSTR2B) (1992) FEBS Lett, 311, pp. 290-294
Vanetti, M., Vogt, G., Hollt, V., The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization (1993) FEBS Lett, 331, pp. 260-266
Rocheville, M., Lange, D.C., Kumar, U., Sasi, R., Patel, R.C., Patel, Y.C., Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers (2000) J. Biol. Chem, 275, pp. 7862-7869
Pfeiffer, M., Koch, T., Schroder, H., Klutzny, M., Kirscht, S., Kreienkamp, H.J., Hollt, V., Schulz, S., Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A) (2001) J. Biol. Chem, 276, pp. 14027-14036
Rens-Domiano, S., Reisine, T., Biochemical and functional properties of somatostatin receptors (1987) J. Neurochem, 1992, p. 58
Schweitzer, P., Madamba, S., Siggins, G.R., Arachidonic acid metabolites as mediators of somatostatin-induced increase of neuronal M-current (1990) Nature, 346, pp. 464-467
Colas, B., Cambillau, C., Buscail, L., Zeggari, M., Esteve, J.P., Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells (1992) Eur. J. Biochem, 207, pp. 1017-1024
Pyronnet, S., Bousquet, C., Najib, S., Azar, R., Laklai, H., Antitumor effects of somatostatin (2008) Mol. Cell. Endocrinol, 286, pp. 230-237
Weckbecker, G., Lewis, I., Albert, R., Schmid, H.A., Hoyer, D., Opportunities in somatostatin research: Biological, chemical and therapeutic aspects (2003) Nat. Rev. Drug Discov, 2, pp. 999-1017
Oberg, K., Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment (2005) Curr. Opin. Oncol, 17, pp. 386-391
Solcia, E., Kloppel, G., Sobin, H., Histological typing of endocrine tumors (2000) World Health Organization International Histological Classification of Tumors
Volante, M., Rosas, R., Allia, E., Granata, R., Baragli, A., Muccioli, G., Papotti, M., Somatostatin, cortistatin and their receptors in tumours (2008) Mol. Cell Endocrinol, 286, pp. 219-229
Reubi, J.C., Peptide receptors as molecular targets for cancer diagnosis and therapy (2003) Endocrinol. Rev, 24, pp. 389-427
Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocrinol. Rev, 24, pp. 28-47
de Herder, W.W., Hofland, L.J., van der Lely, A.J., Lamberts, S.W., Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours (2003) Endocrinol. Relat. Cancer, 10, pp. 451-458
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action (1982) Life Sci, 31, pp. 1133-1140
Susini, C., Buscail, L., Rationale for the use of somatostatin analogs as antitumor agents (1733) Ann. Oncol, 2006, p. 17
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., Weckbecker, G., SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile (2002) Eur. J. Endocrinol, 146, pp. 707-716
Weckbecker, G., Briner, U., Lewis, I., Bruns, C., SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs (2002) Endocrinology, 143, pp. 4123-4130
van der Hoek, J., van der Lelij, A.J., Feelders, R.A., de Herder, W.W., Uitterlinden, P., Poon, K.W., Boerlin, V., Lamberts, S.W., The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients (2005) Clin. Endocrinol. (Oxf), 63, pp. 176-184
Schmid, H.A., Development, mechanism of action and potential applications (2008) Mol. Cell Endocrinol, 286, pp. 69-74
Schmid, H.A., Schoeffter, P., Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors (2004) Neuroendocrinology, 80 (SUPPL. 1), pp. 47-50
Valkema, R., De Jong, M., Bakker, W.H., Breeman, W.A., Kooij, P.P., Lugtenburg, P.J., De Jong, F.H., Krenning, E.P., Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience (2002) Semin. Nucl. Med, 32, pp. 110-122
McCarthy, K.E., Woltering, E.A., Anthony, L.B., In situ radiotherapy with 111In-pentetreotide (2000) Q. J. Nucl. Med, 44, pp. 88-95
Anthony, L.B., Woltering, E.A., Espenan, G.D., Cronin, M.D., Maloney, T.J., McCarthy, K.E., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies (2002) Semin. Nucl. Med, 32, pp. 123-132
Buscombe, J.R., Caplin, M.E., Hilson, A.J., Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors (2003) J. Nucl. Med, 44, pp. 1-6
Slooter, G.D., Breeman, W.A., Marquet, R.L., Krenning, E.P., van Eijck, C.H., Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver (1999) Int. J. Cancer, 81, pp. 767-771
Reubi, J.C., Schar, J.C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J.S., Macke, H.R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) Eur. J. Nucl. Med, 27, pp. 273-282
Reubi, J. C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1338-1347Ginj, M., Chen, J., Walter, M.A., Eltschinger, V., Reubi, J.C., Maecke, H.R., Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy (2005) Clin. Cancer Res, 11, pp. 1136-1145
Ginj, M., Schmitt, J.S., Chen, J., Waser, B., Reubi, J.C., de Jong, M., Schulz, S., Maecke, H.R., Design, synthesis, and biological evaluation of somatostatin-based radiopeptides (2006) Chem. Biol, 13, pp. 1081-1090
O'Donoghue, J.A., Bardies, M., Wheldon, T.E., Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides (1902) J. Nucl. Med, 1995, p. 36
de Jong, M., Breeman, W.A., Valkema, R., Bernard, B.F., Krenning, E.P., Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 13S-17S
Iten, F., Müller, B., Schindler, C., Rochlitz, C., Oertli, D., Mäcke, H.R., Müller-Brand, J., Walter, M.A., Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial (2007) Clin. Cancer Res, 13, pp. 6696-6702
Forrer, F., Valkema, R., Kwekkeboom, D.J., de Jong, M., Krenning, E.P., Neuroendocrine tumors. Peptide receptor radionuclide therapy (2007) Best Pract. Res. Clin. Endocrinol. Metab, 21, pp. 111-129
Forrer, F., Riedweg, I., Maecke, H.R., Mueller-Brand, J., Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma (2008) Q. J. Nucl. Med. Mol. Imaging, 52, pp. 334-340
Wehrmann, C., Senftleben, S., Zachert, C., Muller, D., Baum, R.P., Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC (2007) Cancer Biother. Radiopharm, 22, pp. 406-416
Davi, M.V., Bodei, L., Ferdeghini, M., Falconi, M., Testoni, M., Paganelli, G., Oliani, C., Francia, G., Multidisciplinary approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: A promising proposal (2008) Endocr. Pract, 14, pp. 213-218
Raju, M.R., Eisen, Y., Carpenter, S., Inkret, W.C., Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus (1991) Radiat. Res, 128, pp. 204-209
Geerlings, M. W., Sr.
Geerlings, M. W., Jr.
Scheinberg, D. A. Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med., 1999, 40, 166-176Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., Essler, M., Preclinical Evaluation of the {alpha}-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors (2008) Clin. Cancer Res, 14, pp. 3555-3561
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Reubi, J.C., Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 16436-16441
Janson, E.T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother. Biol. Response Modif, 21, pp. 535-546
Gabriel, M., Decristoforo, C., Donnemiller, E., Ulmer, H., Watfah Rychlinski, C., Mather, S.J., Moncayo, R., An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPAoctreotide for diagnosis of somatostatin receptor-expressing tumors (2003) J. Nucl. Med, 44, pp. 708-716
Czepczynski, R., Parisella, M.G., Kosowicz, J., Mikolajczak, R., Ziemnicka, K., Gryczynska, M., Sowinski, J., Signore, A., Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma (2007) Eur. J. Nucl. Med. Mol. Imaging, 34, pp. 1635-1645
Cwikla, J.B., Mikolajczak, R., Pawlak, D., Buscombe, J.R., Nasierowska-Guttmejer, A., Bator, A., Maecke, H.R., Walecki, J., Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs (2008) J. Nucl. Med, 49, pp. 1060-1065
Vallabhajosula, S., Moyer, B.R., Lister-James, J., McBride, B.J., Lipszyc, H., Lee, H., Bastidas, D., Dean, R.T., Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides (1996) J. Nucl. Med, 37, pp. 1016-1022
Menda, Y., Kahn, D., Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide (2002) Semin. Nucl. Med, 32, pp. 92-96
Blum, J., Handmaker, H., Lister-James, J., Rinne, N., A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules (2000) Chest, 117, pp. 1232-1238
Shah, T., Kulakiene, I., Quigley, A.M., Warbey, V.S., Srirajaskanthan, R., Toumpanakis, C., Hochhauser, D., Caplin, M.E., The role of 99mTc-depreotide in the management of neuroendocrine tumours (2008) Nucl. Med. Commun, 29, pp. 436-440
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R.P., Reubi, J.C., Maecke, H., Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? (2007) Eur. J. Nucl. Med. Mol. Imaging, 34, pp. 982-993
Baum, R., Schmucking, M., Wortmann, R., Muller, M., Zhernosekov, K., Rosch, F., Receptor PET/CT using the Ga-68 labelled somatostatin analog DOTA-1-Nal3-octreotide (DOTA-NOC): Clinical experience in 140 patients (2005) Nuklearmedizin, 44, pp. A57
Hofmann, M., Oei, M., Boerner, A.R., Maecke, H., Geworski, L., Knapp, W.H., Krause, T., Comparison of Ga-68-DOTATOC and Ga-68-DOTANOC for radiopeptide PET (2005) Nuklearmedizin, 44, pp. A58
Win, Z., Rahman, L., Murrell, J., Todd, J., Al-Nahhas, A., The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 506
Traub, T., von Guggenberg, E., Kendler, D., Eisterer, W., Bale, R., Dobrozemsky, G., Gabriel, M., Virgolini, I., First experience with Ga-68-DOTA-lanreotide PET in tumor patients (2005) Nuklearmedizin, 44, pp. A198
Hofmann, M., Maecke, H., Borner, R., Weckesser, E., Schoffski, P., Oei, L., Schumacher, J., Knapp, H., Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data (1751) Eur. J. Nucl. Med, 2001, p. 28
Win, Z., Al-Nahhas, A., Rubello, D., Gross, M.D., Somatostatin receptor PET imaging with Gallium-68 labeled peptides (2007) Q. J. Nucl. Med. Mol. Imaging, 51, pp. 244-250
Meisetschlager, G., Poethko, T., Stahl, A., Wolf, I., Scheidhauer, K., Schottelius, M., Herz, M., Schwaiger, M., (2006) J. Nucl. Med, 47, pp. 566-573
Schottelius, M., Poethko, T., Herz, M., Reubi, J.C., Kessler, H., Schwaiger, M., Wester, H.J., First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography (2004) Clin. Cancer Res, 10, pp. 3593-3606
Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease (1995) Nat. Med, 1, pp. 27-31
Mousa, S.A., Mechamism of angiogensis in vascular disorders: Potential therapeutic targets (1998) Drugs Future, 23, pp. 51-60
Mousa, S.A., Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications (2000) Emerging Ther. Targets, 4, pp. 389-395
Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis (2000) Nat. Med, 6, pp. 389-395
Bogler, O., Mikkelsen, T., Angiogenesis in glioma: Molecular mechanisms and roadblocks to translation (2003) Cancer J, 9, pp. 205-213
Folkman, J., Role of angiogenesis in tumor growth and metastasis (2002) Semin. Oncol, 29, pp. 15-18
Hwang, R., Varner, J., The role of integrins in tumor angiogenesis (2004) Hematol. Oncol. Clin. North Am, 18, pp. 991-1006. , vii
Ellis, L.M., Liu, W., Fan, F., Jung, Y.D., Reinmuth, N., Stoeltzing, O., Takeda, A., Ahmad, S., Synopsis of angiogenesis inhibitors in oncology (2002) Oncology (Williston Park), 16, pp. 14-22
Jin, H., Varner, J., Integrins: Roles in cancer development and as treatment targets (2004) Br. J. Cancer, 90, pp. 561-565
Kumar, C.C., Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis (2003) Curr. Drug Targets, 4, pp. 123-131
Brooks, P.C., Clark, R.A., Cheresh, D.A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Ruoslahti, E., Pierschbacher, M.D., New perspectives in cell adhesion: RGD and integrins (1987) Science, 238, pp. 491-497
Ivaska, J., Heino, J., Adhesion receptors and cell invasion: Mechanisms of integrin-guided degradation of extracellular matrix (2000) Cell Mol. Life Sci, 57, pp. 16-24
Hynes, R.O., Integrins: Versatility, modulation, and signaling in cell adhesion (1992) Cell, 69, pp. 11-25
Felding-Habermann, B., O'Toole, T.E., Smith, J.W., Fransvea, E., Ruggeri, Z.M., Ginsberg, M.H., Hughes, P.E., Mueller, B.M., Integrin activation controls metastasis in human breast cancer (1853) Proc. Natl. Acad. Sci. USA, 2001, p. 98
Reinmuth, N., Liu, W., Ahmad, S.A., Fan, F., Stoeltzing, O., Parikh, A.A., Bucana, C.D., Ellis, L.M., Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice (2003) Cancer Res, 63, pp. 2079-2087
Zhao, Y., Bachelier, R., Treilleux, I., Pujuguet, P., Peyruchaud, O., Baron, R., Clement-Lacroix, P., Clezardin, P., Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases (2007) Cancer Res, 67, pp. 5821-5830
Eliceiri, B.P., Cheresh, D.A., The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development (1999) J. Clin. Invest, 103, pp. 1227-1230
Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 1996, 12, 697-715Horton, M.A., The alpha v beta 3 integrin "vitronectin receptor (1997) Int. J Biochem. Cell Biol, 29, pp. 721-725
Bello, L., Francolini, M., Marthyn, P., Zhang, J., Carroll, R.S., Nikas, D.C., Strasser, J.F., Black, P.M., Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery (2001) Neurosurgery, 49, pp. 380-389
Gurrath, M., Muller, G., Kessler, H., Aumailley, M., Timpl, R., Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides (1992) Eur. J. Biochem, 210, pp. 911-921
Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins (1994) J. Biol. Chem, 269, pp. 20233-20238
Plow, E.F., Haas, T.A., Zhang, L., Loftus, J., Smith, J.W., Ligand binding to integrins (2000) J. Biol. Chem, 275, pp. 21785-21788
Suehiro, K., Smith, J.W., Plow, E.F., The ligand recognition specificity of beta3 integrins (1996) J. Biol. Chem, 271, pp. 10365-10371
Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C.A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Falcioni, R., Cimino, L., Gentileschi, M.P., D'Agnano, I., Zupi, G., Kennel, S.J., Sacchi, A., Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes (1994) Exp. Cell Res, 210, pp. 113-122
Meitar, D., Crawford, S.E., Rademaker, A.W., Cohn, S.L., Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma (1996) J. Clin. Oncol, 14, pp. 405-414
Gasparini, G., Brooks, P.C., Biganzoli, E., Vermeulen, P.B., Bonoldi, E., Dirix, L.Y., Ranieri, G., Cheresh, D.A., Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer (1998) Clin. Cancer Res, 4, pp. 2625-2634
Sengupta, S., Chattopadhyay, N., Mitra, A., Ray, S., Dasgupta, S., Chatterjee, A., Role of alphavbeta3 integrin receptors in breast tumor (2001) J. Exp. Clin. Cancer Res, 20, pp. 585-590
Zitzmann, S., Ehemann, V., Schwab, M., Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo (2002) Cancer Res, 62, pp. 5139-5143
Weber, W.A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H.J., Schwaiger, M., Tumor angiogenesis targeting using imaging agents (2001) Q. J. Nucl. Med, 45, pp. 179-182
Costouros, N.G., Diehn, F.E., Libutti, S.K., Molecular imaging of tumor angiogenesis (2002) J. Cell Biochem. Suppl, 39, pp. 72-78
Van De Wiele, C., Oltenfreiter, R., De Winter, O., Signore, A., Slegers, G., Dierckx, R.A., Tumour angiogenesis pathways: Related clinical issues and implications for nuclear medicine imaging (2002) Eur. J. Nucl. Med. Mol. Imaging, 29, pp. 699-709
Liu, S., Robinson, S.P., Edwards, D.S., Integrin alphaV beta3 directed radiopharmaceutical for tumor imaging (2003) Drugs Future, 28, pp. 551-564
Haubner, R., Wester, H.J., Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies (2004) Curr. Pharm. Des, 10, pp. 1439-1455
Chen, X., Multimodality imaging of tumor integrin alphavbeta3 expression (2006) Mini Rev. Med. Chem, 6, pp. 227-234
Haubner, R., Finsinger, D., Kessler, H., Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alphaVbeta3 integrin for a new cancer therapy (1997) Angew. Chem. Int. Ed. Engl, 36, pp. 1374-1389
Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., Cheresh, D.A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) Cell, 79, pp. 1157-1164
Clezardin, P., Recent insights into the role of integrins in cancer metastasis (1998) Cell Mol. Life Sci, 54, pp. 541-548
Aumailley, M., Gurrath, M., Muller, G., Calvete, J., Timpl, R., Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 (1991) FEBS Lett, 291, pp. 50-54
Haubner, R., Gratias, R., Diefenbach, B., Goodman, S.L., Jonczyk, A., Kessler, H.P., Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin alphaVbeta3 Antagonists (1996) J. Am. Chem. Soc, 118, pp. 7461-7472
Gottschalk, K.E., Kessler, H., The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction (2002) Angew. Chem. Int. Ed. Engl, 41, pp. 3767-3774
Bach II, A.C., Espina, J.R., Jackson, S.A., Stouten, P.F.W., Duke, J.L., Mousa, S.A., DeGrado, W.F., Type II' to Type I -Turn Swap Changes Specificity for Integrins (1996) J. Am. Chem. Soc, 118, pp. 293-294
Muller, G., Gurrath, M., Kessler, H., Pharmacophore refinement of gpIIb/ IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides (1994) J. Comput. Aided Mol. Des, 8, pp. 709-730
Scarborough, R.M., Naughton, M.A., Teng, W., Rose, J.W., Phillips, D.R., Nannizzi, L., Arfsten, A., Charo, I.F., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa (1993) J. Biol. Chem, 268, pp. 1066-1073
Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists (1999) J. Med. Chem, 42, pp. 3033-3040
Eskens, F.A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur. J. Cancer, 39, pp. 917-926
Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD (2005) PLoS Med, 2, pp. e70
Tempia-Caliera, A. A.
Nippgen, J. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285Beekman, K.W., Colevas, A.D., Cooney, K., Dipaola, R., Dunn, R.L., Gross, M., Keller, E.T., Hussain, M., Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design (2006) Clin. Genitourin Cancer, 4, pp. 299-302
Nabors, L.B., Mikkelsen, T., Rosenfeld, S.S., Hochberg, F., Akella, N.S., Fisher, J.D., Cloud, G.A., Grossman, S.A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma (2007) J. Clin. Oncol, 25, pp. 1651-1657
Garanger, E., Boturyn, D., Dumy, P., Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents (2007) Med. Chem, 7, pp. 552-558
MacDonald, T.J., Stewart, C.F., Kocak, M., Goldman, S., Ellenbogen, R.G., Phillips, P., Lafond, D., Kun, L.E., Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012 (2008) J. Clin. Oncol, 26, pp. 919-924
Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Arnaout, M.A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Thumshirn, G., Hersel, U., Goodman, S.L., Kessler, H., Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation (2003) Chemistry, 9, pp. 2717-2725
Wester, H.J., Kessler, H., Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? (1940) J. Nucl. Med, 2005, p. 46
Boturyn, D., Coll, J.L., Garanger, E., Favrot, M.C., Dumy, P., Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis (2004) J. Am. Chem. Soc, 126, pp. 5730-5739
Liu, S., Hsieh, W.Y., Kim, Y.S., Mohammed, S.I., Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer (2005) Bioconjug. Chem, 16, pp. 1580-1588
de Visser, M., Verwijnen, S.M., de Jong, M., Update: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy (2008) Cancer Biother. Radiopharm, 23, pp. 137-157
Meyer, A., Auernheimer, J., Modlinger, A., Kessler, H., Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting (2006) Curr. Pharm. Des, 12, pp. 2723-2747
Psimadas, D., Fani, M., Zikos, C., Xanthopoulos, S., Archimandritis, S.C., Varvarigou, A.D., Study of the labeling of two novel RGD-peptidic derivatives with the precursor [99mTc(H2O)3 (CO)3]+ and evaluation for early angiogenesis detection in cancer (2006) Appl. Radiat. Isot, 64, pp. 151-159
Lee, Y.S., Jeong, J.M., Kim, H.W., Chang, Y.S., Kim, Y.J., Hong, M.K., Rai, G.B., Suh, Y.G., An improved method of 18F peptide labeling: Hydrazone formation with HYNIC-conjugated c(RGDyK) (2006) Nucl. Med. Biol, 33, pp. 677-683
Decristoforo, C., Faintuch-Linkowski, B., Rey, A., von Guggenberg, E., Rupprich, M., Hernandez-Gonzales, I., Rodrigo, T., Haubner, R., 99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression (2006) Nucl. Med. Biol, 33, pp. 945-952
Jia, B., Shi, J., Yang, Z., Xu, B., Liu, Z., Zhao, H., Liu, S., Wang, F., 99mTc-labeled cyclic RGDfK dimer: Initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression (2006) Bioconjug. Chem, 17, pp. 1069-1076
Liu, S., Edwards, D.S., Ziegler, M.C., Harris, A.R., Hemingway, S.J., Barrett, J.A., 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors (2001) Bioconjug. Chem, 12, pp. 624-629
Mitra, A., Coleman, T., Borgman, M., Nan, A., Ghandehari, H., Line, B.R., Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting (2006) J. Control Rel, 114, pp. 175-183
Dijkgraaf, I., Kruijtzer, J.A., Frielink, C., Soede, A.C., Hilbers, H.W., Oyen, W.J., Corstens, F.H., Boerman, O.C., Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists (2006) Nucl. Med. Biol, 33, pp. 953-961
Dijkgraaf, I., Rijnders, A.Y., Soede, A., Dechesne, A.C., van Esse, G.W., Brouwer, A.J., Corstens, F.H., Liskamp, R.M., Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: Implications for tumor targeting and tumor imaging purposes (2007) Org. Biomol. Chem, 5, pp. 935-944
Dijkgraaf, I., Liu, S., Kruijtzer, J.A., Soede, A.C., Oyen, W.J., Liskamp, R.M., Corstens, F.H., Boerman, O.C., Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide (2007) Nucl. Med. Biol, 34, pp. 29-35
Zhang, X., Chen, X., Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent (2007) Appl. Radiat. Isot, 65, pp. 70-78
Alves, S., Correia, J.D., Gano, L., Rold, T.L., Prasanphanich, A., Haubner, R., Rupprich, M., Smith, C.J., In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys) (2007) Bioconjug. Chem, 18, pp. 530-537
Chen, X. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J. Nucl. Med., 2007, 48, 1536-1544Li, Z.B., Wu, Z., Chen, K., Chin, F.T., Chen, X., Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression (1987) Bioconjug. Chem, 2007, p. 18
Li, Z.B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., Chen, X., (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression (2007) J. Nucl. Med, 48, pp. 1162-1171
Li, Z.B., Chen, K., Chen, X., (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression (2008) Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 1100-1108
Edwards, D., Jones, P., Haramis, H., Battle, M., Lear, R., Barnett, D.J., Edwards, C., Godden, V., 99mTc-NC100692 - a tracer for imaging vitronectin receptors associated with angiogenesis: A preclinical investigation (2008) Nucl. Med. Biol, 35, pp. 365-375
Roed, L., Oulie, I., Knuttel, T., Toft, K.G., Hustvedt, S.O., Skotland, T., Metabolism in rats of NC100692, an RGD-peptide for imaging of angiogenesis (2008) J. Pharm. Biomed. Anal, 47, pp. 164-169
Indrevoll, B., Kindberg, G.M., Solbakken, M., Bjurgert, E., Johansen, J.H., Karlsen, H., Mendizabal, M., Cuthbertson, A., NC-100717: A versatile RGD peptide scaffold for angiogenesis imaging (2006) Bioorg. Med.Chem. Lett, 16, pp. 6190-6193
Hua, J., Dobrucki, L.W., Sadeghi, M.M., Zhang, J., Bourke, B.N., Cavaliere, P., Song, J., Sinusas, A.J., Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia (2005) Circulation, 111, pp. 3255-3260
Lindsey, M.L., Escobar, G.P., Dobrucki, L.W., Goshorn, D.K., Bouges, S., Mingoia, J.T., McClister Jr., D.M., Spinale, F.G., Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction (2006) Am. J. Physiol. Heart Circ. Physiol, 290, pp. H232-H239
Bach-Gansmo, T., Danielsson, R., Saracco, A., Wilczek, B., Bogsrud, T.V., Fangberget, A., Tangerud, A., Tobin, D., Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692 (2006) J. Nucl. Med, 47, pp. 1434-1439
Glaser, M., Morrison, M., Solbakken, M., Arukwe, J., Karlsen, H., Wiggen, U., Champion, S., Cuthbertson, A., Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups (2008) Bioconjug. Chem, 19, pp. 951-957
Del Gatto, A., Zaccaro, L., Grieco, P., Novellino, E., Zannetti, A., Novel and selective alpha(v)beta3 receptor peptide antagonist: Design, synthesis, and biological behavior (2006) J. Med. Chem, 49, pp. 3416-3420
de Tullio, P., Delarge, J., Pirotte, B., Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists) (1999) Curr. Med. Chem, 6, pp. 433-455
Escherich, A., Lutz, J., Escrieut, C., Fourmy, D., van Neuren, A.S., Muller, G., Schafferhans, A., Moroder, L., Peptide/ benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors (2000) Biopolymers, 56, pp. 55-76
Herranz, R., Cholecystokinin antagonists: Pharmacological and therapeutic potential (2003) Med. Res. Rev, 23, pp. 559-605
Reubi, J.C., Schaer, J.C., Waser, B., Cholecystokinin(CCK)-A and CCK-B/ gastrin receptors in human tumors (1997) Cancer Res, 57, pp. 1377-1386
Berna, M.J., Jensen, R.T., Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases (2007) Curr. Top. Med. Chem, 7, pp. 1211-1231
Baldwin, G.S., Shulkes, A., CCK receptors and cancer (2007) Curr. Top. Med. Chem, 7, pp. 1232-1238
Reubi, J.C., Targeting CCK receptors in human cancers (2007) Curr. Top. Med. Chem, 7, pp. 1239-1242
Reubi, J.C., Macke, H.R., Krenning, E.P., Candidates for peptide receptor radiotherapy today and in the future (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 67S-75S
Laverman, P., Behe, M., Oyen, W.J., Willems, P.H., Corstens, F.H., Behr, T.M., Boerman, O.C., Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors (2004) Bioconjug. Chem, 15, pp. 561-568
Wank, S.A., Cholecystokinin receptors (1995) Am. J. Physiol, 269, pp. G628-G646
Mansi, R., Tesauro, D., De Capua, A., Fattorusso, R., Caraco, C., Aloj, L., Benedetti, E., Morelli, G., Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (2004) Biopolymers, 76, pp. 527-534
Aloj, L., Panico, M., Caraco, C., Del Vecchio, S., Arra, C., Affuso, A., Accardo, A., Salvatore, M., In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (2004) Cancer Biother. Radiopharm, 19, pp. 93-98
Aloj, L., Caraco, C., Panico, M., Zannetti, A., Del Vecchio, S., Tesauro, D., De Luca, S., Salvatore, M., In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (2004) J. Nucl. Med, 45, pp. 485-494
D'Andrea, L.D., Testa, I., Panico, M., Di Stasi, R., Caraco, C., Tarallo, L., Arra, C., Aloj, L., In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with (99m)Tc-tricarbonyl (2008) Biopolymers, 90, pp. 707-712
Berna, M.J., Tapia, J.A., Sancho, V., Jensen, R.T., Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential (2007) Curr. Opin. Pharmacol, 7, pp. 583-592
De Luca, S., De Capua, A., Saviano, M., Della Moglie, R., Aloj, L., Tarallo, L., Pedone, C., Morelli, G., Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor (2007) Bioorg. Med. Chem, 15, pp. 5845-5853
De Luca, S., Saviano, M., Della Moglie, R., Digilio, G., Bracco, C., Aloj, L., Tarallo, L., Morelli, G., (2006) Chem. Med. Chem, 1, pp. 997-1006
De Luca, S., Morelli, G., Synthesis and characterization of a sulfated and a non-sulfated cyclic CCK8 analogue functionalized with a chelating group for metal labelling (2004) J. Pept. Sci, 10, pp. 265-273
De Luca, S., Ragone, R., Bracco, C., Digilio, G., Aloj, L., Tesauro, D., Saviano, M., Morelli, G., A cyclic CCK8 analogue selective for the cholecystokinin type A receptor: Design, synthesis, NMR structure and binding measurements (2003) Chembiochem, 4, pp. 1176-1187
Morelli, G., De Luca, S., Tesauro, D., Saviano, M., Pedone, C., Dolmella, A., Visentin, R., Mazzi, U., CCK8 peptide derivatized with diphenylphosphine for rhenium labelling: Synthesis and molecular mechanics calculations (2002) J. Pept. Sci, 8, pp. 373-381
Rovati, A.L., Casula, P.L., Da Re, G., Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid)] (1967) Minerva Med, 58, pp. 3656-3670
Rovati, A.L., Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents (1976) Scand. J. Gastroenterol. Suppl, 42, pp. 113-118
Makovec, F., Bani, M., Cereda, R., Chiste, R., Pacini, M.A., Revel, L., Rovati, L.A., Setnikar, I., Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists (1987) Arzneimittelforschung, 37, pp. 1265-1268
Setnikar, I., Bani, M., Cereda, R., Chiste, R., Makovec, F., Pacini, M.A., Revel, L., Anticholecystokinin activities of loxiglumide (1987) Arzneimittelforschung, 37, pp. 1168-1171
Makovec, F., Peris, W., Revel, L., Giovanetti, R., Mennuni, L., Rovati, L.C., Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives (1992) J. Med. Chem, 35, pp. 28-38
Revel, L., Ferrari, F., Makovec, F., Rovati, L.C., Impicciatore, M., Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative (1992) Eur. J. Pharmacol, 216, pp. 217-224
Salerni, B. nhibitory effect of a gastrin receptor antagonist, CR2945, on 1, 2-dimethylhydrazine-induced colorectal cancer in mice. Eur. Surg. Res., 1999, 31, 406-411Giragossian, C., Mierke, D.F., Determination of ligand-receptor interactions of cholecystokinin by nuclear magnetic resonance (2003) Life Sci, 73, pp. 705-713
Okarvi, S. M., Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases (2004) Med. Res. Rev, 24, pp. 357-39
Patel, Y. C., Somatostatin and its receptor family (1999) Front. Neuroendocrinol, 20, pp. 157-198
Lewin, M. J., The somatostatin receptor in the GI tract (1992) Annu. Rev. Physiol, 54, pp. 455-468
Bruno, J. F., Xu, Y., Song, J., Berelowitz, M., Molecular cloning and functional expression of a brain-specific somatostatin receptor (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 11151-11155
Reubi, J. C., Peptide receptors as molecular targets for cancer diagnosis and therapy (2003) Endocrinol. Rev, 24, pp. 389-427
Hofland, L. J., Lamberts, S. W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocrinol. Rev, 24, pp. 28-47
de Herder, W. W., Hofland, L. J., van der Lely, A. J., Lamberts, S. W., Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours (2003) Endocrinol. Relat. Cancer, 10, pp. 451-458
Schmid, H. A., Development, mechanism of action and potential applications (2008) Mol. Cell Endocrinol, 286, pp. 69-74
Schmid, H. A., Schoeffter, P., Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors (2004) Neuroendocrinology, 80 (SUPPL. 1), pp. 47-50
McCarthy, K. E., Woltering, E. A., Anthony, L. B., In situ radiotherapy with 111In-pentetreotide (2000) Q. J. Nucl. Med, 44, pp. 88-95
Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., McCarthy, K. E., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies (2002) Semin. Nucl. Med, 32, pp. 123-132
Buscombe, J. R., Caplin, M. E., Hilson, A. J., Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors (2003) J. Nucl. Med, 44, pp. 1-6
Slooter, G. D., Breeman, W. A., Marquet, R. L., Krenning, E. P., van Eijck, C. H., Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver (1999) Int. J. Cancer, 81, pp. 767-771
Reubi, J. C., Schar, J. C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., Macke, H. R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) Eur. J. Nucl. Med, 27, pp. 273-282
O'Donoghue, J. A., Bardies, M., Wheldon, T. E., Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides (1902) J. Nucl. Med, 1995, p. 36
Iten, F., M ller, B., Schindler, C., Rochlitz, C., Oertli, D., M cke, H. R., M ller-Brand, J., Walter, M. A., Response to [90Yttrium-DOTA] -TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial (2007) Clin. Cancer Res, 13, pp. 6696-6702
Davi, M. V., Bodei, L., Ferdeghini, M., Falconi, M., Testoni, M., Paganelli, G., Oliani, C., Francia, G., Multidisciplinary approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3] -octreotide) and 177Lu DOTATATE ([177Lu-DOTA0, Tyr3] -octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: A promising proposal (2008) Endocr. Pract, 14, pp. 213-218
Raju, M. R., Eisen, Y., Carpenter, S., Inkret, W. C., Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus (1991) Radiat. Res, 128, pp. 204-209
Janson, E. T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother. Biol. Response Modif, 21, pp. 535-546
Cwikla, J. B., Mikolajczak, R., Pawlak, D., Buscombe, J. R., Nasierowska-Guttmejer, A., Bator, A., Maecke, H. R., Walecki, J., Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs (2008) J. Nucl. Med, 49, pp. 1060-1065
Mousa, S. A., Mechamism of angiogensis in vascular disorders: Potential therapeutic targets (1998) Drugs Future, 23, pp. 51-60
Mousa, S. A., Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications (2000) Emerging Ther. Targets, 4, pp. 389-395
Ellis, L. M., Liu, W., Fan, F., Jung, Y. D., Reinmuth, N., Stoeltzing, O., Takeda, A., Ahmad, S., Synopsis of angiogenesis inhibitors in oncology (2002) Oncology (Williston Park), 16, pp. 14-22
Kumar, C. C., Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis (2003) Curr. Drug Targets, 4, pp. 123-131
Brooks, P. C., Clark, R. A., Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Hynes, R. O., Integrins: Versatility, modulation, and signaling in cell adhesion (1992) Cell, 69, pp. 11-25
Eliceiri, B. P., Cheresh, D. A., The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development (1999) J. Clin. Invest, 103, pp. 1227-1230
Plow, E. F., Haas, T. A., Zhang, L., Loftus, J., Smith, J. W., Ligand binding to integrins (2000) J. Biol. Chem, 275, pp. 21785-21788
Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C. A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764
Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H. J., Schwaiger, M., Tumor angiogenesis targeting using imaging agents (2001) Q. J. Nucl. Med, 45, pp. 179-182
Costouros, N. G., Diehn, F. E., Libutti, S. K., Molecular imaging of tumor angiogenesis (2002) J. Cell Biochem. Suppl, 39, pp. 72-78
Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., Cheresh, D. A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) Cell, 79, pp. 1157-1164
Gottschalk, K. E., Kessler, H., The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction (2002) Angew. Chem. Int. Ed. Engl, 41, pp. 3767-3774
Bach II, A. C., Espina, J. R., Jackson, S. A., Stouten, P. F. W., Duke, J. L., Mousa, S. A., DeGrado, W. F., Type II' to Type I -Turn Swap Changes Specificity for Integrins (1996) J. Am. Chem. Soc, 118, pp. 293-294
Scarborough, R. M., Naughton, M. A., Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L., Arfsten, A., Charo, I. F., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa (1993) J. Biol. Chem, 268, pp. 1066-1073
Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists (1999) J. Med. Chem, 42, pp. 3033-3040
Eskens, F. A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur. J. Cancer, 39, pp. 917-926
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Grossman, S. A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma (2007) J. Clin. Oncol, 25, pp. 1651-1657
MacDonald, T. J., Stewart, C. F., Kocak, M., Goldman, S., Ellenbogen, R. G., Phillips, P., Lafond, D., Kun, L. E., Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012 (2008) J. Clin. Oncol, 26, pp. 919-924
Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Arnaout, M. A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Wester, H. J., Kessler, H., Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? (1940) J. Nucl. Med, 2005, p. 46
Liu, S., Hsieh, W. Y., Kim, Y. S., Mohammed, S. I., Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer (2005) Bioconjug. Chem, 16, pp. 1580-1588
Lee, Y. S., Jeong, J. M., Kim, H. W., Chang, Y. S., Kim, Y. J., Hong, M. K., Rai, G. B., Suh, Y. G., An improved method of 18F peptide labeling: Hydrazone formation with HYNIC-conjugated c (RGDyK) (2006) Nucl. Med. Biol, 33, pp. 677-683
Li, Z. B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., Chen, X., (64) Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha (v) beta (3) integrin expression (2007) J. Nucl. Med, 48, pp. 1162-1171
Li, Z. B., Chen, K., Chen, X., (68) Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha (v) beta (3) expression (2008) Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 1100-1108
Lindsey, M. L., Escobar, G. P., Dobrucki, L. W., Goshorn, D. K., Bouges, S., Mingoia, J. T., McClister Jr., D. M., Spinale, F. G., Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction (2006) Am. J. Physiol. Heart Circ. Physiol, 290, pp. H232-H239
Reubi, J. C., Schaer, J. C., Waser, B., Cholecystokinin (CCK) -A and CCK-B/ gastrin receptors in human tumors (1997) Cancer Res, 57, pp. 1377-1386
Berna, M. J., Jensen, R. T., Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases (2007) Curr. Top. Med. Chem, 7, pp. 1211-1231
Baldwin, G. S., Shulkes, A., CCK receptors and cancer (2007) Curr. Top. Med. Chem, 7, pp. 1232-1238
Reubi, J. C., Targeting CCK receptors in human cancers (2007) Curr. Top. Med. Chem, 7, pp. 1239-1242
Reubi, J. C., Macke, H. R., Krenning, E. P., Candidates for peptide receptor radiotherapy today and in the future (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 67S-75S
Wank, S. A., Cholecystokinin receptors (1995) Am. J. Physiol, 269, pp. G628-G646
D'Andrea, L. D., Testa, I., Panico, M., Di Stasi, R., Caraco, C., Tarallo, L., Arra, C., Aloj, L., In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with (99m) Tc-tricarbonyl (2008) Biopolymers, 90, pp. 707-712
Berna, M. J., Tapia, J. A., Sancho, V., Jensen, R. T., Progress in developing cholecystokinin (CCK) /gastrin receptor ligands that have therapeutic potential (2007) Curr. Opin. Pharmacol, 7, pp. 583-592
Rovati, A. L., Casula, P. L., Da Re, G., Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid)] (1967) Minerva Med, 58, pp. 3656-3670
Rovati, A. L., Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents (1976) Scand. J. Gastroenterol. Suppl, 42, pp. 113-118
Peptides for tumour therapy and diagnosis: current status and future directions
The use of peptides as targeting tools has been validated in different applications. In particular radiolabelled peptides with adequate stability, receptor-binding properties and biokinetic behaviour have been investigated as an important class of radiopharmaceuticals for cancer pathology imaging and therapy. This review focuses on recent progress in design and synthetic modifications of small biologically active peptides used in diagnosis and therapy. In particular, we report the current development and optimization of suitable peptides for targeting three relevant biological receptors (CCK, somatostatin, and integrin receptors) involved in specific tumour diseases.
The use of peptides as targeting tools has been validated in different applications. In particular radiolabelled peptides with adequate stability, receptor-binding properties and biokinetic behaviour have been investigated as an important class of radiopharmaceuticals for cancer pathology imaging and therapy. This review focuses on recent progress in design and synthetic modifications of small biologically active peptides used in diagnosis and therapy. In particular, we report the current development and optimization of suitable peptides for targeting three relevant biological receptors (CCK, somatostatin, and integrin receptors) involved in specific tumour diseases.
Peptides for tumour therapy and diagnosis: current status and future directions
No results. |
Peptides for tumour therapy and diagnosis: current status and future directions
Other filter: ([btitle,keywords] "Somatostatin" OR [bt ...
Platella C, Napolitano E, Riccardi C, Musumeci D, Montesarchio D
* Disentangling the Structure-Activity Relationships of Naphthalene Diimides as Anticancer G-Quadruplex-Targeting Drugs (12 views)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print), 2021 Apr 8; 64(7): 3578-3603.
Impact Factor: 7.446
View Export to BibTeX Export to EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (280 views)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
View Export to BibTeX Export to EndNote
Merlino F, Brancaccio D, Yousif AM, Piras L, Campiglia P, Gomez-monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Carotenuto A, Grieco P
* Structure-Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position9 (378 views)
Chemmedchem (ISSN: 1860-7179, 1860-7187, 1860-7179linking), 2016; N/D: N/D-N/D.
Impact Factor: 3.225
View Export to BibTeX Export to EndNote
Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M
* Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma (333 views)
World J Radiol (ISSN: 1949-8470, 1949-8470electronic, 1949-8470linking), 2014 Oct 28; 6(10): 840-845.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (501 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (707 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
View Export to BibTeX Export to EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1999 views)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
View Export to BibTeX Export to EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (410 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (223 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Zaccaro L, Garcia-lopez Mt Gonzalez-muniz RG
* TRPV1 modulators: Structure-activity relationships using a rational combinatorial approach (461 views)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2011 Jun 15; 21(12): 3541-3545.
Impact Factor: 2.554
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (508 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Ciaccio C, Tundo GR, Grasso G, Spoto G, Marasco D, Ruvo M, Gioia M, Rizzarelli E, Coletta M
* Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity (455 views)
J Mol Biol (ISSN: 1089-8638, 0022-2836, 1089-8638electronic), 2009 Feb 6; 385(5): 1556-1567.
Impact Factor: 3.871
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents (464 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2008 Mar 13; 51(5): 1295-1308.
Impact Factor: 4.898
View Export to BibTeX Export to EndNote
Benedetti E, Pedone C, Saviano M
* Structure-activity relationships in peptides: From modelling to rational drug design (529 views)
Front Drug Des And Discov (ISSN: 1574-0889), 2007; 3(1): 539-558.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Vitale RM, Pedone C, De Benedetti PG, Fanelli F
* Structural features of the inactive and active states of the melanin-concentrating hormone receptors: Insights from molecular simulations (538 views)
Proteins (ISSN: 0887-3585, 1097-0134, 1097-0134electronic), 2004 Sep 15; 56(3): 430-448.
Impact Factor: 4.429
View Export to BibTeX Export to EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (472 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (567 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (430 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (397 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (377 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Lastoria S, Muto P, Acampa W, Caraco C, Vergara E, Varrella P, Pezzullo L, Ionna F, Mozzillo N, ListerJames J, Salvatore M
Somatostatin receptor scintigraphy (SRS) with technetium-99m labeled synthetic peptides in melanoma (386 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Muto P, Lastoria S, Vergara E, Caraco C, Varrella P, Bernardy JD, Acampa W, Salvatore M
Tc-99m labeled somatostatin analogs to image tumors expressing specific receptors (250 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1995; 36(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (267 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (293 views)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
* Disentangling the Structure-Activity Relationships of Naphthalene Diimides as Anticancer G-Quadruplex-Targeting Drugs (12 views)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print), 2021 Apr 8; 64(7): 3578-3603.
Impact Factor: 7.446
View Export to BibTeX Export to EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (280 views)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
View Export to BibTeX Export to EndNote
Merlino F, Brancaccio D, Yousif AM, Piras L, Campiglia P, Gomez-monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Carotenuto A, Grieco P
* Structure-Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position9 (378 views)
Chemmedchem (ISSN: 1860-7179, 1860-7187, 1860-7179linking), 2016; N/D: N/D-N/D.
Impact Factor: 3.225
View Export to BibTeX Export to EndNote
Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M
* Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma (333 views)
World J Radiol (ISSN: 1949-8470, 1949-8470electronic, 1949-8470linking), 2014 Oct 28; 6(10): 840-845.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (501 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (707 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
View Export to BibTeX Export to EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1999 views)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
View Export to BibTeX Export to EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (410 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (223 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Zaccaro L, Garcia-lopez Mt Gonzalez-muniz RG
* TRPV1 modulators: Structure-activity relationships using a rational combinatorial approach (461 views)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2011 Jun 15; 21(12): 3541-3545.
Impact Factor: 2.554
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (508 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Ciaccio C, Tundo GR, Grasso G, Spoto G, Marasco D, Ruvo M, Gioia M, Rizzarelli E, Coletta M
* Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity (455 views)
J Mol Biol (ISSN: 1089-8638, 0022-2836, 1089-8638electronic), 2009 Feb 6; 385(5): 1556-1567.
Impact Factor: 3.871
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents (464 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2008 Mar 13; 51(5): 1295-1308.
Impact Factor: 4.898
View Export to BibTeX Export to EndNote
Benedetti E, Pedone C, Saviano M
* Structure-activity relationships in peptides: From modelling to rational drug design (529 views)
Front Drug Des And Discov (ISSN: 1574-0889), 2007; 3(1): 539-558.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Vitale RM, Pedone C, De Benedetti PG, Fanelli F
* Structural features of the inactive and active states of the melanin-concentrating hormone receptors: Insights from molecular simulations (538 views)
Proteins (ISSN: 0887-3585, 1097-0134, 1097-0134electronic), 2004 Sep 15; 56(3): 430-448.
Impact Factor: 4.429
View Export to BibTeX Export to EndNote
Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (472 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (567 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (430 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (397 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (377 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Lastoria S, Muto P, Acampa W, Caraco C, Vergara E, Varrella P, Pezzullo L, Ionna F, Mozzillo N, ListerJames J, Salvatore M
Somatostatin receptor scintigraphy (SRS) with technetium-99m labeled synthetic peptides in melanoma (386 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Muto P, Lastoria S, Vergara E, Caraco C, Varrella P, Bernardy JD, Acampa W, Salvatore M
Tc-99m labeled somatostatin analogs to image tumors expressing specific receptors (250 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1995; 36(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (267 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (293 views)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
30 Records (24 excluding Abstracts).
Total impact factor: 110.599 (92.057 excluding Abstracts).
Total 5 year impact factor: 118.065 (93.819 excluding Abstracts).
Total impact factor: 110.599 (92.057 excluding Abstracts).
Total 5 year impact factor: 118.065 (93.819 excluding Abstracts).
1177 views. Last view on Thursday 08 June 2023, 1:17:50
ibb.cnr.it
